Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 8:00 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 193 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Triostat Clear all

Conditions: Metastatic Breast Cancer, Thyroid Dysfunction
Interventions: Triiodothyronine (T3); Drug
Lead sponsor: Aultman Health Foundation; Other
Eligibility: 18 Years to 105 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Canton, Ohio

Conditions: Recurrent Medulloblastoma, Recurrent Ependymoma
Interventions: Irinotecan, Temozolomide, Bevacizumab, Omburtamab I-131, Liothyronine, SSKI, Dexamethasone, Antipyretic, Antihistamine, anti-emetics; Drug
Lead sponsor: Pediatric Brain Tumor Consortium; Network
Eligibility: Up to 21 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 3
States / cities: Los Angeles, California • New York, New York • Cincinnati, Ohio

Conditions: Healthy Participants
Interventions: TAK-994; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 2
States / cities: Tempe, Arizona • Lincoln, Nebraska

Conditions: Prostate Cancer
Interventions: Rapamycin 3mg, Rapamycin 6mg, Radical prostatectomy; Drug · Procedure
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 120 Years · Male only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 3
States / cities: Baltimore, Maryland • Ann Arbor, Michigan • Durham, North Carolina

Conditions: Cataracts
Interventions: Toric IOL (SN60T3); Device
Lead sponsor: Alcon Research; Industry
Eligibility: 21 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Prostate Cancer
Interventions: radiation therapy; Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1991 – 2005
U.S. locations: 1
States / cities: New York, New York

Conditions: Pediatric Cancer, Adolescent and Young Adult Cancer
Interventions: ReSPECT; Behavioral
Lead sponsor: Connecticut Children's Medical Center; Other
Eligibility: 15 Years to 25 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Attention Deficit Disorder With Hyperactivity
Interventions: MPH (Concerta), MPH (Ritalin), Atomoxetine (ATO), Guanfacine (GFC); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: Not listed
Enrollment: 17,418 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Titusville, New Jersey

Conditions: Arthritis, Rheumatoid
Interventions: Abatacept; Drug
Lead sponsor: Arthritis Northwest PLLC; Industry
Eligibility: Not listed
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Spokane, Washington

Conditions: Brain Cancer
Interventions: eSNAP, Questionnaires; Behavioral
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Overweight and Obesity, Depression, Postpartum, Mother (Person)
Interventions: Madres para la Salud; Behavioral
Lead sponsor: Arizona State University; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 177 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Stage IIIA Non-Small Cell Lung Cancer
Interventions: Neoadjuvant Cisplatin, nab-paclitaxel, Adjuvant Cisplatin,nab-paclitaxel, Adjuvant cisplatin+pemetrexed or cisplatin+gemcitabine; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 9
States / cities: Tampa, Florida • Atlanta, Georgia • Kansas City, Kansas + 6 more

Conditions: Rectal Cancer
Interventions: Chemo with concomitant Capecitabine and KD018; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Fasting, Delayed Gastric Emptying, Aspiration Pneumonia, Respiratory Aspiration of Gastric Content
Interventions: Gastric Ultrasound Baseline Scans, Acetaminophen Absorption Test (AAT), Gastric Ultrasound Serial Scans; Diagnostic Test
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 2 Years to 18 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Brain Cancer, Brain Stem Glioma
Interventions: Radioactive iodine-labeled monoclonal antibody omburtamab, External Beam Radiotherapy; Drug · Radiation
Lead sponsor: Y-mAbs Therapeutics; Industry
Eligibility: 2 Years to 21 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2022
U.S. locations: 2
States / cities: New York, New York

Conditions: Auscultation Training, Health Professions Education
Interventions: Traditional Auscultation Training, Ventriloscope Simulation Training; Behavioral
Lead sponsor: Youngstown State University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Youngstown, Ohio

Conditions: Mental Health, Suicide
Interventions: Messaging, Wait list control; Behavioral · Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 89 Years
Enrollment: 355 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Canandaigua, New York

Conditions: Thyroid Disease, Healthy
Interventions: Not listed
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy Volunteers
Interventions: Soticlestat; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Oral Squamous Cell Carcinoma
Interventions: PRV211 (Intraoperative Cisplatin System), PRV111 (Cisplatin Transmucosal System), PRV131 (Cisplatin Intratumoral Injectable); Drug
Lead sponsor: Privo Technologies; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 4
States / cities: Duarte, California • Miami, Florida • Chicago, Illinois + 1 more

Conditions: Nasopharyngeal Carcinoma
Interventions: Genetically modified CTLs; Biological
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Not listed
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Bacterial Infection
Interventions: Apramycin (EBL-1003); Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Contraception, Hypogonadism
Interventions: Oral Testosterone, Leuprolide (Lupron), Dutasteride; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Depression
Interventions: T3; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 64 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Rochester, Minnesota

Search by objective public record fields.

Study of Euthyroid Hypothyroxinemia in Metastatic Breast Carcinoma

131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma

A Study of Different Forms of TAK-994 in Healthy Adults

Sirolimus Before Surgery in Treating Patients With Advanced Localized Prostate Cancer

Low Cylinder Toric

Radiation Therapy in Treating Patients With Prostate Cancer

Improving Communication Between AYA Oncology Patients and Clinicians: A Patient-Centered Intervention

A Study of Label Compliance for Attention Deficit/Hyperactivity Disorder (ADHD) Medications in Japan

Real-world Clinical Efficacy of Abatacept in the T3 Data Registry

Refining and Testing the Electronic Social Network Assessment Program (eSNAP)

Madres Para la Salud (Mothers for Health)

Cisplatin and Nab-paclitaxel for (N2) Defined NSCLC

Pilot Trial of KD018 With Neo-Adjuvant Concurrent Chemo-Radiation Therapy in Patients With Locally Advanced Rectal Cancer

Gastric Assessment of Pediatric Patients Undergoing Surgery

Convection-Enhanced Delivery of 124I-Omburtamab for Patients With Non-Progressive Diffuse Pontine Gliomas Previously Treated With External Beam Radiation Therapy

Ventriloscope Simulation Stethoscope Training in PT and AT Students (VENTAS)

Public Messaging to Increase Treatment Seeking for Veterans at Risk for Suicide

Pharmacogenomic Response to Thyrotropin-Releasing Hormone Stimulation in Healthy Volunteers: The Influence of a Common Type 2 Deiodinase Genetic Polymorphism on Serum T3

A Study of Soticlestat Tablets in Healthy Adults

A Study Evaluating the Safety and Efficacy of PRV111, PRV211, and PRV131 in Subjects With Oral and Lung Cancers

LMP1- and LMP2-Specific CTLs to Patients With EBV-Positive NPC (NATELLA)

Safety of Intravenous Apramycin in Adults

Oral Androgens in Man-3 (ORAL T-3) Pharmacokinetics of Oral Testosterone

Acceleration and Relapse Prevention With Triiodothyronine (T3) as an Adjunct to Electroconvulsive Therapy (ECT)